Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Marubeni Expands Pharma Sales Biz into Africa with Phillips Investment
Japanese trading house Marubeni said on August 19 that it has completed an investment in Phillips Healthcare, expanding the geographic reach of its pharmaceutical sales platform to Asia, China, the Middle East, and Africa. Phillips Healthcare, a leading distributor of…
To read the full story
Related Article
- Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
- Marubeni Pharma Targets Doubling Profits by FY2035 with 2 New Deals Each Year
November 25, 2025
- Marubeni Invests in Healthcare Product Distributor in Africa
January 29, 2025
BUSINESS
- Former Takeda CEO Yasuchika Hasegawa Dies at 80
September 11, 2026
- Takeda R&D Chief Plump to Retire in June 2027
September 11, 2026
- Lasker Win “Not the Finish Line” for Chugai Researchers; Next-Gen Drug Advances
September 11, 2026
- Daiichi Sankyo Wins 203 Billion Yen Lawsuit over Fortis Bid
September 11, 2026
- Silchester Emerges as Suzuken’s Top Shareholder with 10.03% Voting Stake
September 11, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…